Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENLON-PLUS vs ADDERALL 20
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enlon-Plus (neostigmine methylsulfate and glycopyrrolate) is a combination of a reversible acetylcholinesterase inhibitor (neostigmine) and an anticholinergic agent (glycopyrrolate). Neostigmine inhibits acetylcholinesterase, increasing acetylcholine concentration at cholinergic synapses, enhancing neuromuscular transmission. Glycopyrrolate counteracts muscarinic side effects (e.g., bradycardia, excessive secretions) without affecting nicotinic actions.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
Reversal of non-depolarizing neuromuscular blocking agents after surgery,Off-label: Treatment of myasthenia gravis (neostigmine component)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy,Off-label: Treatment-resistant depression, obesity, cognitive enhancement
1 to 2 m L (0.5 to 1 mg neostigmine methylsulfate with 0.2 to 0.4 mg glycopyrrolate) IV over 1 minute; may repeat in 10-15 minutes if needed; maximum total dose: 5 m L.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
Terminal elimination half-life: 3.5–4.5 hours (prolonged in hepatic impairment).
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
Neostigmine: Hydrolyzed by cholinesterases and metabolized in the liver via microsomal enzymes. Glycopyrrolate: Not significantly metabolized; eliminated unchanged in urine and bile.
Primarily hepatic via CYP2D6 and, to a lesser extent, CYP2C19, CYP3A4, and CYP2C9. Metabolites include 4-hydroxyamphetamine, alpha-hydroxyamphetamine, and norephedrine.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites.
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
Plasma protein binding: 55–65%, primarily to albumin.
16% (primarily albumin).
Vd: 0.8–1.2 L/kg, indicating distribution into total body water.
3.2-5.6 L/kg; indicates extensive tissue distribution.
Oral: 70–80% (first-pass effect); IM: 100%.
Oral IR: ~90%; ER: ~90%.
Cr Cl 10-50 m L/min: Use 50% of dose. Cr Cl <10 m L/min: Use 25% of dose. Adjust based on neostigmine component due to renal excretion.
e GFR 15-29 m L/min: 50% of usual dose. e GFR < 15 m L/min: avoid use due to accumulation risk. Hemodialysis: not recommended.
No specific adjustment required; neostigmine minimally hepatically metabolized.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: avoid use.
0.04 mg/kg neostigmine methylsulfate with 0.02 mg/kg glycopyrrolate IV; may repeat in 10-15 minutes if needed; maximum single dose: 2 m L.
Children 3-5 years: 2.5 mg orally once daily; increase by 2.5 mg weekly. Children 6 years and older: 5 mg once or twice daily; increase by 5 mg weekly. Maximum dose: 40 mg/day (immediate-release). Weight-based: 0.3-1.5 mg/kg/day (immediate-release).
Use with caution; consider lower initial doses due to potential renal impairment; monitor for bradycardia and excessive cholinergic effects.
Initial: 2.5 mg once or twice daily; increase slowly by 2.5 mg increments at weekly intervals. Use lowest effective dose due to increased sensitivity and risk of cardiovascular adverse effects.
Should be used only when facilities for immediate endotracheal intubation, artificial respiration, and oxygen therapy are available. Bradycardia and cardiac arrest have occurred. Administer in the presence of an anesthesiologist or other qualified clinician.
Abuse and dependence: Amphetamines have a high potential for abuse, which can lead to dependence and serious cardiovascular events. Misuse may cause sudden death or serious cardiovascular adverse events.
Risk of severe bradycardia, hypotension, and cardiac arrest. Use caution in patients with asthma, epilepsy, bradyarrhythmias, recent myocardial infarction, or hyperthyroidism. May increase bronchial secretions. Avoid in patients with mechanical obstruction of the gastrointestinal or urinary tract.
Cardiovascular: Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities.,Psychiatric: Exacerbation of pre-existing psychosis, mania, or aggression; new-onset psychosis or mania.,Growth suppression: Long-term use in children may suppress growth.,Seizures: May lower seizure threshold in patients with seizure disorders.,Serotonin syndrome: Risk when used with other serotonergic drugs.,Peripheral vasculopathy: Including Raynaud's phenomenon.
Known hypersensitivity to neostigmine, glycopyrrolate, or any component. Contraindicated in patients with peritonitis, mechanical intestinal obstruction, or urinary tract obstruction.
Hypersensitivity to amphetamine or any component of the formulation,Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use or within 14 days of MAO inhibitors (risk of hypertensive crisis)
No specific food interactions are reported. Maintain adequate hydration. Avoid excessive caffeine or alcohol, which may affect heart rate or fluid balance.
High-fat meals can delay absorption of Adderall. Acidic foods (e.g., citrus fruits, juices) and vitamin C may decrease absorption; avoid within 1 hour of dosing. Caffeine and other stimulants may increase side effects. Alcohol should be avoided. Grapefruit juice may increase amphetamine levels, so limit or avoid.
First trimester: No adequate studies in pregnant women; animal studies not available. Risk cannot be ruled out. Second/third trimester: Potential fetal toxicity (respiratory depression, bradycardia) if used near term. Avoid use during labor due to risk of neonatal respiratory depression.
First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of fetal growth restriction, preterm birth, neonatal withdrawal syndrome (irritability, poor feeding), and persistent pulmonary hypertension. Chronic use may impair fetal development.
Not recommended. Unknown M/P ratio. Atropine and pralidoxime (components of ENLON-PLUS) may enter breast milk; potential for infant anticholinergic effects and gastrointestinal disturbances.
Excreted into breast milk; M/P ratio approximately 2.5–7.5. Relative infant dose estimated at 5–14% of maternal weight-adjusted dose. Potential for decreased appetite, insomnia, and growth suppression in breastfed infants. American Academy of Pediatrics recommends use only if benefit outweighs risk, with close monitoring.
No established dose adjustments. Increased plasma volume and renal clearance in pregnancy may reduce drug concentrations; however, no pharmacokinetic studies available. Titrate to effect with caution.
Due to increased renal clearance and expanded plasma volume, total amphetamine exposure may decrease, potentially requiring dose increase (monitor clinical response). However, insufficient data to recommend fixed adjustments; individualize based on symptom control and tolerability.
ENLON-PLUS (neostigmine/glycopyrrolate) is used for reversal of non-depolarizing neuromuscular blockade. Neostigmine inhibits acetylcholinesterase, increasing ACh at the neuromuscular junction; glycopyrrolate is an anticholinergic to counteract muscarinic side effects (bradycardia, excessive secretions). Monitor heart rate closely; glycopyrrolate may cause tachycardia. Administer IV slowly over 1 minute. Onset is 5-10 minutes; peak effect at 10-20 minutes. Use with caution in patients with bradycardia, asthma, or peptic ulcer disease.
Adderall 20 mg is a mixed amphetamine salt formulation (75% dextroamphetamine, 25% levoamphetamine). Monitor for cardiovascular adverse effects; consider baseline ECG in patients with cardiac risk factors. Avoid in patients with structural cardiac abnormalities, cardiomyopathy, or arrhythmias. Use with caution in patients with hypertension, hyperthyroidism, or glaucoma. May exacerbate tics and Tourette syndrome. Administer first dose upon awakening; avoid afternoon doses due to insomnia risk. Monitor growth in children; may cause weight loss and growth suppression. Assess for potential for abuse and dependence; use lowest effective dose.
This medication is given to reverse muscle relaxants after surgery.,You may experience changes in heart rate; tell your doctor if you feel palpitations or chest discomfort.,Dry mouth and blurred vision are possible side effects due to the glycopyrrolate component.,Inform your healthcare provider if you have a history of heart problems, asthma, or stomach ulcers.,You may feel temporary muscle weakness or twitching as the medication works.
Take exactly as prescribed; do not crush or chew extended-release capsules.,Take early in the morning to avoid trouble sleeping.,Avoid taking with high-fat meals as it may delay absorption.,Do not drink alcohol while taking this medication.,Report any chest pain, shortness of breath, or fainting immediately.,Avoid driving or operating heavy machinery until you know how Adderall affects you.,Store at room temperature away from moisture and heat.,Keep out of reach of children and pets.,Do not share your medication with others; it is a controlled substance.,Inform your doctor if you have a history of heart disease, high blood pressure, seizures, or mental health conditions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENLON-PLUS vs ADDERALL 20, answered by our medical review team.
ENLON-PLUS is a Cholinesterase Inhibitor Combination that works by Enlon-Plus (neostigmine methylsulfate and glycopyrrolate) is a combination of a reversible acetylcholinesterase inhibitor (neostigmine) and an anticholinergic agent (glycopyrrolate). Neostigmine inhibits acetylcholinesterase, increasing acetylcholine concentration at cholinergic synapses, enhancing neuromuscular transmission. Glycopyrrolate counteracts muscarinic side effects (e.g., bradycardia, excessive secretions) without affecting nicotinic actions.. ADDERALL 20 is a CNS Stimulant that works by Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENLON-PLUS and ADDERALL 20 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENLON-PLUS is: 1 to 2 m L (0.5 to 1 mg neostigmine methylsulfate with 0.2 to 0.4 mg glycopyrrolate) IV over 1 minute; may repeat in 10-15 minutes if needed; maximum total dose: 5 m L.. The standard adult dose of ADDERALL 20 is: Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENLON-PLUS and ADDERALL 20 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENLON-PLUS is classified as Category C. First trimester: No adequate studies in pregnant women; animal studies not available. Risk cannot be ruled out. Second/third trimester: Potential fetal toxicity (respiratory depres. ADDERALL 20 is classified as Category C. First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.